Search hospitals > Florida > Orlando
Florida Hospital Cancer Institute
Claim this profileOrlando, Florida 32804
Global Leader in Lung Cancer
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
215 reported clinical trials
8 medical researchers
Summary
Florida Hospital Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Lung Cancer, T-Lymphoblastic Leukemia/Lymphoma, Non-Small Cell Lung Cancer, Leukemia, Lymphoma and other specialties. Florida Hospital Cancer Institute is involved with conducting 215 clinical trials across 191 conditions. There are 8 research doctors associated with this hospital, such as Carlos Alemany, Mohamedtaki A. Tejani, Guru P Sonpavde, MD, and Robert Holloway, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
metastatic
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderFLT3 positive
Top PIs
Carlos AlemanyAdventHealth Orlando5 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
22 reported clinical trials
62 drugs studied
Mohamedtaki A. TejaniAdventHealth Orlando3 years of reported clinical research
Studies Stomach Cancer
Studies Pancreatic Cancer
18 reported clinical trials
35 drugs studied
Guru P Sonpavde, MDDana Farber Cancer Institute4 years of reported clinical research
Studies Bladder Cancer
Studies Cancer
15 reported clinical trials
22 drugs studied
Robert Holloway, MDAdventHealth Cancer Institute2 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Cancer
12 reported clinical trials
23 drugs studied
Clinical Trials running at Florida Hospital Cancer Institute
Ovarian Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Uterine Tumors
Colorectal Cancer
Acute Myeloid Leukemia
Bladder Cancer
Cancer
Solid Tumors
Glioblastoma
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Florida Hospital Cancer Institute?
Florida Hospital Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Lung Cancer, T-Lymphoblastic Leukemia/Lymphoma, Non-Small Cell Lung Cancer, Leukemia, Lymphoma and other specialties. Florida Hospital Cancer Institute is involved with conducting 215 clinical trials across 191 conditions. There are 8 research doctors associated with this hospital, such as Carlos Alemany, Mohamedtaki A. Tejani, Guru P Sonpavde, MD, and Robert Holloway, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.